NASDAQ:ZFGNZafgen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.78 +0.01 (+1.61 %) (As of 04/10/2020 06:36 AM ET) Add Compare Share Today's Range$0.75Now: $0.78▼$0.8050-Day Range$0.66MA: $0.94▼$1.3052-Week Range$0.62Now: $0.78▼$2.91Volume37,033 shsAverage Volume220,756 shsMarket Capitalization$29.04 millionP/E RatioN/ADividend YieldN/ABeta0.21 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingZafgen has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.59, Zafgen has a potential upside of 492.7% from its current price of $0.78.Amount of Analyst CoverageZafgen has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesZafgen has received 345 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZafgen has received 316 “underperform” votes. (Add your “underperform” vote.)Community SentimentZafgen has received 52.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote “Outperform” if you believe ZFGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZFGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZafgen does not currently pay a dividend.Dividend GrowthZafgen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zafgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 14.20% of the stock of Zafgen is held by insiders.Percentage Held by Institutions66.72% of the stock of Zafgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Zafgen is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zafgen is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZafgen has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZFGN Previous Symbol CUSIPN/A CIK1374690 Webhttp://www.zafgen.com/ Phone617-622-4003Debt Debt-to-Equity Ratio0.28 Current Ratio5.87 Quick Ratio5.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book0.54Profitability EPS (Most Recent Fiscal Year)($1.07) Net Income$-45,410,000.00 Net MarginsN/A Return on Equity-59.48% Return on Assets-41.12%Miscellaneous Employees38 Outstanding Shares37,470,000Market Cap$29.04 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive ZFGN News and Ratings via Email Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ZFGN Rates by TradingView Zafgen (NASDAQ:ZFGN) Frequently Asked Questions How has Zafgen's stock been impacted by COVID-19 (Coronavirus)? Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN shares have decreased by 8.8% and is now trading at $0.7750. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Zafgen? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen. When is Zafgen's next earnings date? Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Zafgen. How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.19). View Zafgen's earnings history. What price target have analysts set for ZFGN? 5 analysts have issued twelve-month price objectives for Zafgen's shares. Their forecasts range from $0.78 to $8.00. On average, they anticipate Zafgen's stock price to reach $4.59 in the next twelve months. This suggests a possible upside of 492.7% from the stock's current price. View analysts' price targets for Zafgen. Has Zafgen been receiving favorable news coverage? Media headlines about ZFGN stock have trended very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zafgen earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutZafgen. Are investors shorting Zafgen? Zafgen saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 565,000 shares, a drop of 38.7% from the February 13th total of 921,700 shares. Based on an average daily trading volume, of 623,900 shares, the days-to-cover ratio is currently 0.9 days. Approximately 1.7% of the company's stock are short sold. View Zafgen's Current Options Chain. Who are some of Zafgen's key competitors? Some companies that are related to Zafgen include CELYAD SA/ADR (CYAD), Mustang Bio (MBIO), CymaBay Therapeutics (CBAY), Obseva (OBSV), AcelRx Pharmaceuticals (ACRX), Savara (SVRA), Strongbridge Biopharma (SBBP), Aptinyx (APTX), GlycoMimetics (GLYC), Harrow Health (HROW), Galectin Therapeutics (GALT), Axovant Gene Therapies (AXGT), Humanigen (HGEN), PhaseBio Pharmaceuticals (PHAS) and Sierra Oncology (SRRA). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), Endologix (ELGX), SCYNEXIS (SCYX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE). Who are Zafgen's key executives? Zafgen's management team includes the following people: Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)Ms. Patricia L. Allen, Chief Financial Officer (Age 57)Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)Dr. James E. Vath, Head of Discovery & Devel. (Age 58)Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46) What is Zafgen's stock symbol? Zafgen trades on the NASDAQ under the ticker symbol "ZFGN." How do I buy shares of Zafgen? Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Zafgen's stock price today? One share of ZFGN stock can currently be purchased for approximately $0.78. How big of a company is Zafgen? Zafgen has a market capitalization of $29.04 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe. View additional information about Zafgen. What is Zafgen's official website? The official website for Zafgen is http://www.zafgen.com/. How can I contact Zafgen? Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: What are popular green investing opportunities?
